Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

2.110 +0.010 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development
Via ACCESSWIRE
Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website
Via ACCESSWIRE
Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614
Via ACCESSWIRE
Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study
Via ACCESSWIRE
Dr. Lynn Kirkpatrick, Featured Speaker to Discuss Ensysce Overdose Protection Platform at DCAT Seminar
Via ACCESSWIRE
Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock
Via ACCESSWIRE
Ensysce Biosciences Provides Corporate Update
Via ACCESSWIRE
Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study
Via ACCESSWIRE
Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial
Via ACCESSWIRE
Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection
Via ACCESSWIRE
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Via ACCESSWIRE
Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering
Via ACCESSWIRE
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
Via ACCESSWIRE
Ensysce Biosciences Reports Third Quarter 2022 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614
Via ACCESSWIRE
Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational
Via ACCESSWIRE
Ensysce Biosciences Issues 2023 Shareholder Letter
Via ACCESSWIRE
Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering
Via ACCESSWIRE
Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A
Via ACCESSWIRE
Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product
Via ACCESSWIRE
Ensysce Biosciences Announces First Subjects Dosed in Second Human Abuse Potential Study
Via ACCESSWIRE
Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR
Via ACCESSWIRE
Ensysce Biosciences Reminds Shareholders to Vote at Upcoming Special Meeting
Via ACCESSWIRE
Ensysce Biosciences to Present at Benzinga All Access Event on Friday, September 23, 2022
Via ACCESSWIRE
Ensysce Biosciences Announces Results of Special Meeting of Stockholders
Via ACCESSWIRE
Ensysce Biosciences Debuts Redesigned Company Website to Highlight its TAAP(TM) and MPAR(TM) Technologies and Growing Product Pipeline
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces Participation in Upcoming Conferences
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.